The GOLGB1 Knockout NCI-H1975 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population engineered to disrupt expression of the GOLGB1 gene in the NCI-H1975 human lung adenocarcinoma epithelial cell line. This heterogeneous pool is generated via direct ribonucleoprotein-mediated gene disruption and subsequent selection, avoiding single-cell cloning to preserve the inherent genetic diversity of the host line while achieving efficient target-gene ablation. The polyclonal format provides a robust, stable loss-of-function model suitable for functional studies without clonal artifacts.
The NCI-H1975 cell line was derived from a female non-small cell lung cancer patient and harbors activating EGFR L858R and resistance-conferring T790M mutations. These dual mutations drive constitutive EGFR signaling and confer resistance to first-generation tyrosine kinase inhibitors, establishing NCI-H1975 as a clinically relevant in vitro model for investigating acquired drug resistance mechanisms and evaluating next-generation EGFR-targeted therapies. The cells maintain epithelial morphology and are widely used in oncogenic signaling and pharmacology research.
GOLGB1 encodes giantin, a cis-Golgi golgin that acts as a vesicle tethering factor essential for maintaining Golgi ribbon integrity and facilitating COPI vesicle docking. Giantin interacts physically with USO1/p115 and GOLGA2/GM130 to form a tethering complex, and its function is regulated by ARF1, Rab GTPases, and Golgi stress signals. Downstream, giantin-dependent tethering ensures proper secretory cargo maturation, glycosylation of cell surface receptors, and extracellular matrix secretion, thereby influencing protein trafficking fidelity and cellular homeostasis.
In the NCI-H1975 context, GOLGB1 knockout disrupts Golgi architecture and impairs secretory pathway function, potentially altering the glycosylation and trafficking of EGFR and other receptor tyrosine kinases. This can modify downstream signaling cascades, influencing proliferation, survival, and drug sensitivity. Moreover, defective secretion of ECM components and autocrine factors may attenuate migratory and invasive capacities, making this model uniquely suited to explore the intersection of Golgi biology and metastatic traits in EGFR-mutant lung cancer.
These polyclonal knockout cells enable a broad range of experimental applications, including VSVG-GFP trafficking assays to quantify ER-to-Golgi transport kinetics, lectin blotting to assess global glycosylation changes, and immunofluorescence microscopy with anti-GM130 and anti-giantin antibodies to visualize Golgi disorganization. Cancer-focused studies can utilize transwell migration and invasion assays, drug sensitivity profiling with EGFR inhibitors such as osimertinib, and secretion assays for matrix metalloproteases or other cargo. Additional analyses such as Western blotting and RT-qPCR confirm target knockout and probe downstream effectors. For further technical support, please contact Ascent Research.
